Cancelled by the investigator Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)

Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030328

Enrollment

Unknown

Registered

2020-02-28

Start date

2020-03-02

Completion date

Unknown

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Acetylcysteine inhaled via tracheal tube

Control group:Placebo (saline) inhaled via tracheal tube

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the "Diagnosis and Treatment Program for COVID-19"(trial version 6th); (2) Patients =18 years of age with tracheal intubation; (3) Agree to participate in the trial, and the patient, the legal guardian or the person in charge of the medical institution signed the informed consent through paper signature, electronic signature of mobile phone software, or voice authorization.

Exclusion criteria

Exclusion criteria: 1.Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.; 2.Obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumor; 3.Use in vitro life support (ECMO, ECCO2R); 4.Patients with bronchial asthma, peptic ulcer, and patients allergic to acetylcysteine; 5.Any potential violation of test compliance or any other circumstance affecting safety and effectiveness evaluation that may exist, which the researchers believe is not suitable for patients participating in the study.

Design outcomes

Primary

Measure	Time frame
Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;	—

Secondary

Measure	Time frame
Sputum suction amount;Circulation indicators: blood pressure, heart rate;	—

Countries

China

Contacts

Public ContactYun Lin

Union Hospital, Tongji Medical College, Huazhong University of Science & Technology

frank0130@126.com+86 13986268403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026